secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001628280-25-023129
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook
--------------------------------------------------------------------------------

- Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
- Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.
- Adjusted EBITDA of $4.9M, up from $0.7M in prior year.
- Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.
- Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/0001628280-25-023129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/cdxc-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer